Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
No one on the platform currently holds DICE.
No tracked institution reports a position in DICE as of their last filing.
No one on the platform has traded DICE yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$DICE DICE Therapeutics, Inc. (NASDAQ:DICE): A Promising Biopharmaceutical Company Poised for Growth https://beyondspx.com/article/dice-therapeutics-inc-nasdaq-dice-a-promising-biopharmaceutical-company-poised-for-growth
View on StockTwits ↗
BTIG⬆️PT $PTGX $67 was $51/Buy, after ascribing💳to PN-881 based on the implied EV of $DICE's ACQ by $LLY, (on only P1 data), risk adj'd by 50%. BTIG thinks PN-881's differentiated specificity could support preferential positioning as the dominant oral IL-17 inhibitor: $ucbjy $nvs
View on StockTwits ↗$DICE DICE Therapeutics, Inc. (NASDAQ:DICE): A Promising Biopharmaceutical Company Poised for Growth http://beyondspx.com/2024/08/04/dice-therapeutics-inc-nasdaqdice-a-promising-biopharmaceutical-company-poised-for-growth/
View on StockTwits ↗
$PRQR By "like these" he meant $DICE and $MORF deals, early ish stage assets, novel science.
View on StockTwits ↗
$NERV - Investment perspective on Minerva Neurosciences vs. Dice Molecules ( $DICE ) in September 2023. Next fiscal quarter end is on 30th of September 2023 https://www.macroaxis.com/competition/NERV/DICE/Minerva-vs-Dice #portfolio_prospective #better_portfolio #diversify
View on StockTwits ↗
$NVO, $DICE and $BLDR. Strong technicals stocks and near a new high. https://www.chartmill.com/stock/stock-screener?sid=16&f=p_pg10,v1_50b500,s_str,s_nnh,exch_us&v=3&timeframe=DAILY&type=CANDLES&months=0.05&width=720&cl=F&o1=3&o2=3&o3=1&op1=200,16711680&op2=50,255&utm_source=Strong_Stocks_near_New_High&utm_medium=stocktwits&utm_campaign=screen
View on StockTwits ↗
DICE Therapeutics's neutral rating reiterated at HC Wainwright. $48.00 PT. www.marketbeat.com/stocks/NASDAQ/DICE/price-target/ $DICE
View on StockTwits ↗
DICE Therapeutics, Inc. Files SEC Form 8-K $DICE https://www.marketbeat.com/stocks/NASDAQ/DICE/sec-filings/
View on StockTwits ↗
$LLY $DICE Lilly Completes Acquisition of DICE Therapeutics https://www.stocktitan.net/news/LLY/lilly-completes-acquisition-of-dice-nbus3ix4jls2.html
View on StockTwits ↗$NVTAQ - Should I Trade Invitae Corp and take over Dice Molecules Holdings ( $DICE ) in September? Next financial report is on 14th of November 2023 https://www.macroaxis.com/invest/pair-correlation/NVTA/DICE/Invitae-vs-Dice #portfolio_prospective #better_portfolio #diversify
View on StockTwits ↗
$DICE trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $47.59 Vol: 4.33M.
View on StockTwits ↗$DRUG - What is better Bright Minds or Dice Molecules ( $DICE )? https://www.macroaxis.com/competition/DRUG/DICE/Bright-vs-Dice #portfolio_prospective #better_portfolio #diversify
View on StockTwits ↗
From 7/5/2023, looking back across 22 Month-Ends for DICE, Percentage Change of Average Monthly Price had More Positives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $DICE #DICE #DICEStock #TickerDD #DICEPrice https://www.youtube.com/watch?v=-2146826273
View on StockTwits ↗New 52 week highs for $DICE, $BA and $MAR https://www.chartmill.com/stock/stock-screener?f=p_pg10,v1_50b500,s_nh,exch_us&v=3&utm_source=stocktwits&utm_medium=New_52_week_high_today&utm_content=screener&utm_campaign=social_tracking
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2023-08-08 | $-0.65 | $-0.74 | -13.8% |
| 2023-05-11 | $-0.59 | $-0.54 | +8.5% |
| 2023-03-15 | $-0.49 | $-0.51 | -4.1% |
| 2022-11-09 | $-0.61 | $-0.55 | +9.8% |
| 2022-08-11 | $-0.56 | $-0.58 | -3.6% |
| 2022-05-12 | $-0.54 | $-0.50 | +7.4% |
| 2022-03-21 | $-0.58 | $-0.44 | +24.1% |
| 2021-11-12 | $0.50 | $2.30 | +360.0% |
| $1.8B |
| — |
| KDNYChinook Therapeutics, Inc. | $40.39 | +0.22% | $2.7B | — |
| LBPHLongboard Pharmaceuticals, Inc. | $59.98 | — | $2.3B | — |
Source: Financial Modeling Prep · peers by sector/industry